First real-world analysis of Merck's Ebola vaccine reveals 84% efficacy during DRC outbreak

First real-world analysis of Merck's Ebola vaccine reveals 84% efficacy during DRC outbreak

Source: 
Fierce Pharma
snippet: 

When a deadly outbreak of the Ebola virus spread through the Democratic Republic of Congo in 2018, Merck’s then-unapproved vaccine was quickly deployed to help address the crisis and provide protection to hundreds of thousands of recipients. Now, four years after that epidemic ended, a new analysis offers a clearer picture on the vaccine’s real-world effectiveness.